Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
2 Magnificent Dividend Stocks to Buy and Hold Forever
09:45am, Monday, 14'th Oct 2024
These companies have compelling track records.
Here's Why Novartis (NVS) is a Strong Momentum Stock
10:55am, Thursday, 10'th Oct 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Swiss competition authority closes Novartis probe without consequences
01:38am, Thursday, 10'th Oct 2024
Switzerland's COMCO competition commission terminated an investigation against Novartis into possibly using blocking patents, without consequences, it said on Thursday.
NVS or LLY: Which Is the Better Value Stock Right Now?
12:48pm, Wednesday, 09'th Oct 2024
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Novartis (NVS) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for underval
5 Low-Leverage Stocks to Buy Buoyed by Impressive Tech Earnings
11:03am, Wednesday, 09'th Oct 2024
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You can buy SAFRY, NVS, KEX, ACGL and LMB.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
09:51am, Monday, 07'th Oct 2024
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Novartis: Value Continues To Build With Double-Digit Percentage Growth Products
02:18pm, Monday, 30'th Sep 2024
Kesimpta continues to do well as a self-administered drug for the treatment of patients with relapsing multiple sclerosis; Q2 2024 sales of $799 million, which is growth of 65% YOY. Pluvicto, as a tre
Novartis: Best Performing Big Pharma Of Past 6 Months Still Looks A Solid Long-Term Bet
11:46am, Thursday, 26'th Sep 2024
Novartis shares have risen over 20% in the past 6 months, making it the best-performing global pharmaceutical stock, with strong profitability and manageable debt. Despite some declining revenues from
SOMERVILLE, Mass.--(BUSINESS WIRE)--Generate:Biomedicines (“Generate”) today announced a multi-target collaboration with Novartis (NYSE: NVS) to discover and develop protein therapeutics across mu
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
10:52pm, Wednesday, 18'th Sep 2024
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Dru
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
10:16am, Wednesday, 18'th Sep 2024
The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
04:24am, Wednesday, 18'th Sep 2024
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs. CEO Vas Narasimhan said the company was researching treatments that deal with
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
03:36am, Wednesday, 18'th Sep 2024
Vas Narasimhan, CEO of Novartis, says the pharmaceutical company does not plan to follow competitors in entering into the weight loss drugs market.
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
01:11pm, Tuesday, 17'th Sep 2024
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
12:55pm, Tuesday, 17'th Sep 2024
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi
